Risks and benefits of celecoxib to prevent recurrent adenomas.
Psaty
Bruce M
BM
Potter
John D
JD
D000236:Adenoma / Q000517:prevention & control*; D018256:Adenomatous Polyps / Q000517:prevention & control; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced; D000068579:Celecoxib; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016609:Neoplasms, Second Primary / Q000517:prevention & control; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D055502:Secondary Prevention; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib